Journal
DRUG DISCOVERY TODAY
Volume 12, Issue 5-6, Pages 241-248Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2007.01.003
Keywords
-
Categories
Funding
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059800] Funding Source: NIH RePORTER
- NIDDK NIH HHS [R01 DK059800, R01 DK059800-07] Funding Source: Medline
Ask authors/readers for more resources
Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor (AR) ligands that might change the future of androgen therapy dramatically. With improved pharmacokinetic characteristics and tissue-selective pharmacological activities, SARMs are expected to greatly extend the clinical applications of androgens to osteoporosis, muscle wasting, male contraception and diseases of the prostate. Mechanistic studies with currently available SARMs will help to define the contributions of differential tissue distribution, tissue-specific expression of 5 alpha tau-reductase, ligand-specific regulation of gene expression and AR interactions with tissue-specific coactivators to their observed tissue selectivity, and lead to even greater expansion of selective anabolic therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available